JP2012515353A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515353A5 JP2012515353A5 JP2011546408A JP2011546408A JP2012515353A5 JP 2012515353 A5 JP2012515353 A5 JP 2012515353A5 JP 2011546408 A JP2011546408 A JP 2011546408A JP 2011546408 A JP2011546408 A JP 2011546408A JP 2012515353 A5 JP2012515353 A5 JP 2012515353A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- subject
- amount
- biological sample
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 110
- 238000000034 method Methods 0.000 claims description 55
- 239000000710 homodimer Substances 0.000 claims description 32
- -1 Bc12 Proteins 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 239000000556 agonist Substances 0.000 claims description 19
- 239000012472 biological sample Substances 0.000 claims description 15
- 239000000523 sample Substances 0.000 claims description 14
- 239000000090 biomarker Substances 0.000 claims description 13
- 238000003556 assay Methods 0.000 claims description 8
- 239000000833 heterodimer Substances 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 230000004850 protein–protein interaction Effects 0.000 claims description 4
- 102100032311 Aurora kinase A Human genes 0.000 claims description 3
- 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 claims description 3
- 102100021633 Cathepsin B Human genes 0.000 claims description 3
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 claims description 3
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 claims description 3
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims description 3
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims description 3
- 102100022334 Dihydropyrimidine dehydrogenase [NADP(+)] Human genes 0.000 claims description 3
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 claims description 3
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 3
- 102100025403 Epoxide hydrolase 1 Human genes 0.000 claims description 3
- 108010008599 Forkhead Box Protein M1 Proteins 0.000 claims description 3
- 102100023374 Forkhead box protein M1 Human genes 0.000 claims description 3
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 claims description 3
- 102100036534 Glutathione S-transferase Mu 1 Human genes 0.000 claims description 3
- 102100036528 Glutathione S-transferase Mu 3 Human genes 0.000 claims description 3
- 101000798300 Homo sapiens Aurora kinase A Proteins 0.000 claims description 3
- 101000971203 Homo sapiens Bcl-2-binding component 3, isoforms 1/2 Proteins 0.000 claims description 3
- 101000971209 Homo sapiens Bcl-2-binding component 3, isoforms 3/4 Proteins 0.000 claims description 3
- 101000898449 Homo sapiens Cathepsin B Proteins 0.000 claims description 3
- 101001081590 Homo sapiens DNA-binding protein inhibitor ID-1 Proteins 0.000 claims description 3
- 101000902632 Homo sapiens Dihydropyrimidine dehydrogenase [NADP(+)] Proteins 0.000 claims description 3
- 101001077852 Homo sapiens Epoxide hydrolase 1 Proteins 0.000 claims description 3
- 101000868643 Homo sapiens G2/mitotic-specific cyclin-B1 Proteins 0.000 claims description 3
- 101001071694 Homo sapiens Glutathione S-transferase Mu 1 Proteins 0.000 claims description 3
- 101001071716 Homo sapiens Glutathione S-transferase Mu 3 Proteins 0.000 claims description 3
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 3
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 claims description 3
- 101000624631 Homo sapiens M-phase inducer phosphatase 2 Proteins 0.000 claims description 3
- 101000979629 Homo sapiens Nucleoside diphosphate kinase A Proteins 0.000 claims description 3
- 101001051706 Homo sapiens Ribosomal protein S6 kinase beta-1 Proteins 0.000 claims description 3
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 claims description 3
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims description 3
- 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 claims description 3
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 3
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 claims description 3
- 102100023325 M-phase inducer phosphatase 2 Human genes 0.000 claims description 3
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 claims description 3
- 102000036673 PRAME Human genes 0.000 claims description 3
- 108060006580 PRAME Proteins 0.000 claims description 3
- 102100028588 Protein ZNRD2 Human genes 0.000 claims description 3
- 102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 claims description 3
- 101150001535 SRC gene Proteins 0.000 claims description 3
- 101150093699 Scube2 gene Proteins 0.000 claims description 3
- 102100028932 Signal peptide, CUB and EGF-like domain-containing protein 2 Human genes 0.000 claims description 3
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 claims description 3
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 3
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 claims description 3
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 claims description 3
- 108050008367 Transmembrane emp24 domain-containing protein 7 Proteins 0.000 claims description 3
- 102000008817 Trefoil Factor-1 Human genes 0.000 claims description 3
- 108010088412 Trefoil Factor-1 Proteins 0.000 claims description 3
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims description 3
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 claims description 3
- 108010048626 Y-Box-Binding Protein 1 Proteins 0.000 claims description 3
- 102100022224 Y-box-binding protein 1 Human genes 0.000 claims description 3
- 101150113535 chek1 gene Proteins 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 238000004904 shortening Methods 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 4
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 230000002596 correlated effect Effects 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 claims 1
- 102100021572 Bcl-2-binding component 3, isoforms 1/2 Human genes 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010073069 Hepatic cancer Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 238000000225 bioluminescence resonance energy transfer Methods 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000875 corresponding effect Effects 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- JXLVPHOTGHZUCE-ZSIUJALASA-N methyl n-[4-[5-chloro-2-[(1s)-1-[[(e)-3-[5-chloro-2-(tetrazol-1-yl)phenyl]prop-2-enoyl]amino]-3-morpholin-4-yl-3-oxopropyl]-1h-imidazol-4-yl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=C(Cl)NC([C@H](CC(=O)N2CCOCC2)NC(=O)\C=C\C=2C(=CC=C(Cl)C=2)N2N=NN=C2)=N1 JXLVPHOTGHZUCE-ZSIUJALASA-N 0.000 claims 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- 238000004393 prognosis Methods 0.000 description 6
- 102100021573 Bcl-2-binding component 3, isoforms 3/4 Human genes 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 2
- 101000871228 Homo sapiens Diablo IAP-binding mitochondrial protein Proteins 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14502909P | 2009-01-15 | 2009-01-15 | |
| US61/145,029 | 2009-01-15 | ||
| PCT/US2010/021272 WO2010083463A1 (en) | 2009-01-15 | 2010-01-15 | Methods of determining patient response by measurement of her-2 expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014006601A Division JP5615986B2 (ja) | 2009-01-15 | 2014-01-17 | Ｈｅｒ−２発現の測定による患者の反応を判定する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012515353A JP2012515353A (ja) | 2012-07-05 |
| JP2012515353A5 true JP2012515353A5 (https=) | 2013-03-07 |
Family
ID=42340111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546408A Withdrawn JP2012515353A (ja) | 2009-01-15 | 2010-01-15 | Ｈｅｒ−２発現の測定による患者の反応を判定する方法 |
| JP2014006601A Active JP5615986B2 (ja) | 2009-01-15 | 2014-01-17 | Ｈｅｒ−２発現の測定による患者の反応を判定する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014006601A Active JP5615986B2 (ja) | 2009-01-15 | 2014-01-17 | Ｈｅｒ−２発現の測定による患者の反応を判定する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20100233732A1 (https=) |
| EP (1) | EP2387717B1 (https=) |
| JP (2) | JP2012515353A (https=) |
| KR (1) | KR20110120890A (https=) |
| CN (1) | CN102439452B (https=) |
| AU (1) | AU2010204576A1 (https=) |
| BR (1) | BRPI1007048A2 (https=) |
| CA (1) | CA2749817A1 (https=) |
| ES (1) | ES2526519T3 (https=) |
| IL (1) | IL214067A0 (https=) |
| SG (1) | SG172984A1 (https=) |
| WO (1) | WO2010083463A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040229294A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
| US20040091850A1 (en) * | 2002-11-08 | 2004-05-13 | Travis Boone | Single cell analysis of membrane molecules |
| US7402398B2 (en) | 2003-07-17 | 2008-07-22 | Monogram Biosciences, Inc. | Measuring receptor homodimerization |
| US8357277B2 (en) | 2007-11-27 | 2013-01-22 | Laboratory Corp. of America Holdings | Enhanced method for detecting and/or quantifying an analyte in a sample |
| CA2711843C (en) * | 2007-12-20 | 2018-11-13 | Laboratory Corporation Of America Holdings | Her-2 diagnostic methods |
| US11401344B2 (en) | 2008-12-01 | 2022-08-02 | Laboratory Corporation Of America Holdings | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients |
| US8470542B2 (en) * | 2008-12-01 | 2013-06-25 | Laboratory Corporation Of America Holdings | Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95 |
| US20120295259A1 (en) * | 2011-05-19 | 2012-11-22 | Laboratory Corporation Of America Holdings | Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients |
| SG172983A1 (en) | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-3 |
| MX338883B (es) | 2010-07-27 | 2016-05-04 | Genomic Health Inc | Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata. |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| FR2993668B1 (fr) * | 2012-07-17 | 2015-07-03 | Cisbio Bioassays | Methode theranostique basee sur la detection de dimeres her2-her2 |
| WO2014165855A1 (en) | 2013-04-05 | 2014-10-09 | Laboratory Corporation Of America Holdings | Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation |
| CN107003323B (zh) | 2014-11-25 | 2019-06-04 | 文塔纳医疗系统公司 | 使用化学连接和半抗原转移的邻近测定法 |
| WO2017014694A1 (en) * | 2015-07-23 | 2017-01-26 | National University Of Singapore | Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment |
| CN108780089B (zh) | 2016-03-15 | 2020-09-08 | 美国控股实验室公司 | 评估细胞间的蛋白质相互作用的方法 |
| ES2897217T3 (es) | 2016-09-30 | 2022-02-28 | Hoffmann La Roche | Anticuerpos biespecíficos frente a p95HER2 |
| JP6922444B2 (ja) * | 2016-11-11 | 2021-08-18 | コニカミノルタ株式会社 | 蛍光ナノ粒子を用いた、病理学的完全奏効（ｐＣＲ）の予測を支援するための検査支援方法 |
| US20210239702A1 (en) * | 2018-06-14 | 2021-08-05 | Memorial Sloan Kettering Cancer Center | Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies |
| KR102317202B1 (ko) * | 2018-10-19 | 2021-10-25 | 주식회사 프로티나 | 유방암 재발 예측 방법 |
| KR102936489B1 (ko) | 2022-03-14 | 2026-03-09 | 부산대학교 산학협력단 | 백금계 항암제에 대한 난소암 환자의 약물 반응성 예측용 다중 바이오마커 조성물 및 이를 이용한 진단방법 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU707440B2 (en) * | 1994-03-29 | 1999-07-08 | Celltech Therapeutics Limited | Antibodies against E-selectin |
| SE9601676D0 (sv) * | 1996-04-30 | 1996-04-30 | Ulf Landegren | Improved probing of specific mucleic acids |
| US6335479B1 (en) * | 1998-10-13 | 2002-01-01 | Dai Nippon Printing Co., Ltd. | Protective sheet for solar battery module, method of fabricating the same and solar battery module |
| US6541214B1 (en) * | 1998-11-13 | 2003-04-01 | Oregon Heath Science University | N-terminally truncated HER-2/neu protein as a cancer prognostic indicator |
| US6682887B1 (en) * | 1999-04-30 | 2004-01-27 | Aclara Biosciences, Inc. | Detection using degradation of a tagged sequence |
| US6627400B1 (en) * | 1999-04-30 | 2003-09-30 | Aclara Biosciences, Inc. | Multiplexed measurement of membrane protein populations |
| US20040248150A1 (en) * | 1999-04-02 | 2004-12-09 | Sharat Singh | Methods employing oligonucleotide-binding e-tag probes |
| US6514700B1 (en) * | 1999-04-30 | 2003-02-04 | Aclara Biosciences, Inc. | Nucleic acid detection using degradation of a tagged sequence |
| US6322980B1 (en) * | 1999-04-30 | 2001-11-27 | Aclara Biosciences, Inc. | Single nucleotide detection using degradation of a fluorescent sequence |
| US6673550B2 (en) * | 1999-04-30 | 2004-01-06 | Aclara Biosciences, Inc. | Electrophoretic tag reagents comprising fluorescent compounds |
| US7037654B2 (en) * | 1999-04-30 | 2006-05-02 | Aclara Biosciences, Inc. | Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents |
| US20030092012A1 (en) * | 2001-11-09 | 2003-05-15 | Ahmed Chenna | Methods for detecting a plurality of analytes by chromatography |
| US20030235832A1 (en) * | 2000-06-21 | 2003-12-25 | Ahmed Chenna | Multiplexed analysis by chromatographic separation of molecular tags |
| US6649351B2 (en) * | 1999-04-30 | 2003-11-18 | Aclara Biosciences, Inc. | Methods for detecting a plurality of analytes by mass spectrometry |
| US7001725B2 (en) * | 1999-04-30 | 2006-02-21 | Aclara Biosciences, Inc. | Kits employing generalized target-binding e-tag probes |
| US6162593A (en) * | 1999-10-26 | 2000-12-19 | Wyatt; Marion F. | Diisopropylbenzene containing solvent and method of developing flexographic printing plates |
| DE19963849A1 (de) * | 1999-12-30 | 2001-07-12 | Giesecke & Devrient Gmbh | Datenträger mit gedrucktem Sicherheitselement |
| US7306904B2 (en) * | 2000-02-18 | 2007-12-11 | Olink Ab | Methods and kits for proximity probing |
| MY133839A (en) * | 2000-03-14 | 2007-11-30 | Shell Int Research | Process for the carbonylation of pentenenitrile |
| GB0007911D0 (en) * | 2000-03-30 | 2000-05-17 | Novartis Ag | Organic compounds |
| US7537938B2 (en) * | 2000-04-28 | 2009-05-26 | Monogram Biosciences, Inc. | Biomarker detection in circulating cells |
| US20030207300A1 (en) * | 2000-04-28 | 2003-11-06 | Matray Tracy J. | Multiplex analytical platform using molecular tags |
| US7160735B2 (en) * | 2000-04-28 | 2007-01-09 | Monogram Biosciences, Inc. | Tagged microparticle compositions and methods |
| US7771929B2 (en) * | 2000-04-28 | 2010-08-10 | Monogram Biosciences, Inc. | Tag library compounds, compositions, kits and methods of use |
| US20040067498A1 (en) * | 2000-04-28 | 2004-04-08 | Ahmed Chenna | Detection of nucleic acid sequences by cleavage and separation of tag-containing structures |
| US6630296B2 (en) * | 2000-08-08 | 2003-10-07 | Aclara Biosciences, Inc. | Multiplexed enzymatic assays |
| EP1236740B1 (de) * | 2001-02-28 | 2012-07-18 | Bio Life Science Forschungs- und Entwicklungsges.m.b.H. | Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind |
| US7183388B2 (en) * | 2001-03-30 | 2007-02-27 | The Regents Of The University Of California | Anti-MUC-1 single chain antibodies for tumor targeting |
| WO2002094998A2 (en) * | 2001-05-21 | 2002-11-28 | Aclara Biosciences, Inc. | Analyzing phosphorylated proteins |
| PL373962A1 (en) * | 2001-05-21 | 2005-09-19 | Aclara Biosciences, Inc. | Methods and compositions for analyzing proteins |
| WO2002097112A2 (en) * | 2001-05-26 | 2002-12-05 | Aclara Biosciences, Inc. | Catalytic amplification of multiplexed assay signals |
| WO2003055439A2 (en) * | 2001-07-18 | 2003-07-10 | The Regents Of The University Of California | Her2/neu target antigen and use of same to stimulate an immune response |
| AU2002319613A1 (en) * | 2001-07-19 | 2003-03-03 | Signet Laboratories, Inc. | Human tissue specific drug screening procedure |
| GB2378245A (en) * | 2001-08-03 | 2003-02-05 | Mats Nilsson | Nucleic acid amplification method |
| WO2003033741A1 (en) * | 2001-10-16 | 2003-04-24 | Aclara Biosciences, Inc. | Universal e-tag primer and probe compositions and methods |
| US7045311B2 (en) * | 2001-10-25 | 2006-05-16 | Monogram Biosciences, Inc. | Whole cell assay systems for cell surface proteases |
| US6659577B2 (en) * | 2001-12-06 | 2003-12-09 | Hewlett-Packard Development Company, L.P. | Dual flat springs for tool-less slide installation |
| US7135174B2 (en) * | 2002-01-07 | 2006-11-14 | Amgen Fremont, Inc. | Antibodies directed to PDGFD and uses thereof |
| ES2352180T3 (es) * | 2002-02-26 | 2011-02-16 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Anticuerpo monoclonal de anti-tenascina humana. |
| US6949347B2 (en) * | 2002-03-05 | 2005-09-27 | Aclara Biosciences, Inc. | Multiplex analysis using membrane-bound sensitizers |
| CA2992643C (en) * | 2002-03-13 | 2019-06-18 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
| WO2003085374A2 (en) * | 2002-04-02 | 2003-10-16 | Aclara Biosciences, Inc. | Multiplexed assays using electrophoretically separated molecular tags |
| US20040248151A1 (en) * | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
| US7332580B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US20090111127A1 (en) * | 2002-05-21 | 2009-04-30 | Monogram Biosciences Inc. | Surface Receptor Complexes as Biomarkers |
| US20040229299A1 (en) * | 2002-05-21 | 2004-11-18 | Badal M. Youssouf | Intracellular complexes as biomarkers |
| US20040229380A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
| US20040229294A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
| US20040229293A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | Surface receptor complexes as biomarkers |
| US7402397B2 (en) * | 2002-05-21 | 2008-07-22 | Monogram Biosciences, Inc. | Detecting and profiling molecular complexes |
| US20040175765A1 (en) * | 2002-07-05 | 2004-09-09 | Sharat Singh | Cell-screening assay and composition |
| ES2392525T3 (es) * | 2002-07-15 | 2012-12-11 | F. Hoffmann-La Roche Ag | Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4 |
| JP4443407B2 (ja) * | 2002-07-25 | 2010-03-31 | アクララ バイオサイエンシーズ， インコーポレイテッド | レセプターオリゴマー形成の検出 |
| CA2493671A1 (en) * | 2002-07-26 | 2004-02-05 | Aclara Biosciences, Inc. | Lipophilic electrophoretic probes |
| US20040091850A1 (en) * | 2002-11-08 | 2004-05-13 | Travis Boone | Single cell analysis of membrane molecules |
| CA2521077A1 (en) * | 2003-04-01 | 2004-10-28 | Monogram Biosciences, Inc. | Erbb surface receptor complexes as biomarkers |
| US20100291594A1 (en) * | 2003-07-17 | 2010-11-18 | Laboratory Corporation Of America Holdings | ErbB Surface Receptor Complexes as Biomarkers |
| US7402398B2 (en) * | 2003-07-17 | 2008-07-22 | Monogram Biosciences, Inc. | Measuring receptor homodimerization |
| US20060204966A1 (en) * | 2003-08-01 | 2006-09-14 | Spector Neil L | Treatment of cancers expressing p95 erbb2 |
| WO2005019470A2 (en) * | 2003-08-11 | 2005-03-03 | Monogram Biosciences, Inc. | Detecting and profiling molecular complexes |
| WO2005017493A2 (en) * | 2003-08-15 | 2005-02-24 | Smithkline Beecham Corporation | Biomarkers in cancer |
| US20050106571A1 (en) * | 2003-10-02 | 2005-05-19 | The Regents Of The University Of California | Mammalian T1R3 sweet taste receptors |
| EP1681983A4 (en) * | 2003-10-14 | 2008-12-10 | Monogram Biosciences Inc | RECEPTOR TYROSINE KINASE SIGNAL PATH ANALYSIS FOR DIAGNOSIS AND THERAPY |
| CN1842540B (zh) * | 2004-07-09 | 2012-07-04 | 中外制药株式会社 | 抗-磷脂酰肌醇蛋白聚糖3抗体 |
| US20080254497A1 (en) * | 2004-10-15 | 2008-10-16 | Monogram Biosciences, Inc. | Response Predictors for Erbb Pathway-Specific Drugs |
| DE602005023529D1 (de) * | 2004-11-03 | 2010-10-21 | Iris Molecular Diagnostics Inc | Homogener nachweis von analyten |
| US7939267B2 (en) * | 2004-11-04 | 2011-05-10 | Laboratory Corporation Of America Holdings | Detection of activation of endothelial cells as surrogate marker for angiogenesis |
| US7862995B2 (en) * | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
| US20060212956A1 (en) * | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
| JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US7700299B2 (en) * | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| CN1928563B (zh) * | 2005-09-09 | 2010-04-28 | 上海张江生物技术有限公司 | 乳腺癌的免疫组化诊断试剂盒和测试片 |
| US8357277B2 (en) * | 2007-11-27 | 2013-01-22 | Laboratory Corp. of America Holdings | Enhanced method for detecting and/or quantifying an analyte in a sample |
| CN101230390A (zh) * | 2007-12-07 | 2008-07-30 | 湖北大学 | 一种用于妇科恶性肿瘤早期筛选的基因芯片及其检测方法 |
| CA2711843C (en) * | 2007-12-20 | 2018-11-13 | Laboratory Corporation Of America Holdings | Her-2 diagnostic methods |
| US8470542B2 (en) * | 2008-12-01 | 2013-06-25 | Laboratory Corporation Of America Holdings | Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95 |
| SG172983A1 (en) * | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-3 |
-
2010
- 2010-01-15 SG SG2011051000A patent/SG172984A1/en unknown
- 2010-01-15 WO PCT/US2010/021272 patent/WO2010083463A1/en not_active Ceased
- 2010-01-15 JP JP2011546408A patent/JP2012515353A/ja not_active Withdrawn
- 2010-01-15 BR BRPI1007048A patent/BRPI1007048A2/pt not_active Application Discontinuation
- 2010-01-15 ES ES10732178.8T patent/ES2526519T3/es active Active
- 2010-01-15 CN CN201080009544.4A patent/CN102439452B/zh not_active Expired - Fee Related
- 2010-01-15 KR KR1020117018898A patent/KR20110120890A/ko not_active Withdrawn
- 2010-01-15 EP EP10732178.8A patent/EP2387717B1/en not_active Revoked
- 2010-01-15 US US12/688,766 patent/US20100233732A1/en not_active Abandoned
- 2010-01-15 CA CA2749817A patent/CA2749817A1/en not_active Abandoned
- 2010-01-15 AU AU2010204576A patent/AU2010204576A1/en not_active Abandoned
-
2011
- 2011-07-13 IL IL214067A patent/IL214067A0/en unknown
-
2014
- 2014-01-17 JP JP2014006601A patent/JP5615986B2/ja active Active
- 2014-07-02 US US14/322,317 patent/US20140370523A1/en not_active Abandoned
-
2016
- 2016-06-15 US US15/183,151 patent/US20170082626A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012515353A5 (https=) | ||
| CA2749817A1 (en) | Methods of determining patient response by measurement of her-2 expression | |
| Pantel et al. | Circulating tumor cells in prostate cancer: from discovery to clinical utility | |
| JP2014074724A5 (https=) | ||
| US8153380B2 (en) | Gene expression markers for colorectal cancer prognosis | |
| Ross | Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome | |
| Geng et al. | Diagnostic and prognostic value of plasma and tissue ubiquitin‐like, containing PHD and RING finger domains 1 in breast cancer patients | |
| Villaflor et al. | Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer | |
| Garczyk et al. | AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection | |
| Zhao et al. | Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy | |
| Nisman et al. | Serum thymidine kinase 1 activity in breast cancer | |
| Witzel et al. | Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial | |
| WO2012125411A1 (en) | Methods of predicting prognosis in cancer | |
| Sjöström et al. | C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer | |
| Lobo et al. | Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression | |
| Sieuwerts et al. | Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting | |
| US20140100188A1 (en) | Phenotyping tumor-infiltrating leukocytes | |
| Yao et al. | Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: A meta-analysis | |
| Siddappa et al. | Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse | |
| Wu et al. | Development and validation of a 10-gene signature for predicting recurrence risk in HR+/HER2-early breast cancer undergoing chemo-endocrine therapy | |
| Shen et al. | Predicting the immune landscape of invasive breast carcinoma based on the novel signature of immune‐related lncRNA | |
| US7354713B2 (en) | Method of using estrogen-related receptor gamma (ERRγ) status to determine prognosis and treatment strategy for breast cancer, method of using ERRγ as a therapeutic target for treating breast cancer, method of using ERRγ to diagnose breast cancer, and method of using ERRγ to identify individuals predisposed to breast cancer | |
| AU2010276324A1 (en) | Phenotyping tumor-infiltrating leukocytes | |
| Fisher et al. | CD151 gene and protein expression provides independent prognostic information for patients with adenocarcinoma of the esophagus and gastroesophageal junction treated by esophagectomy | |
| WO2001004343A9 (en) | A method for determining the prognosis of cancer patients by measuring levels of bag expression |